Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG-60366
- Development stage
- Phase 1
- Lead developer
- BeOne Medicines
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
BG-60366 is a chimeric degradation activating compound (CDAC) designed to selectively degrade mutant epidermal growth factor receptor (EGFR) proteins. It is an orally administered small molecule developed for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations. The drug works by promoting the targeted degradation of mutated EGFR, which drives tumor growth in NSCLC. This mechanism distinguishes it from traditional kinase inhibitors by eliminating the disease-driving protein rather than merely inhibiting its activity. BG-60366 is currently being evaluated in phase 1 clinical trials for safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with EGFR-mutant NSCLC[1][2][3][4][5][6].
- Other names
- BG 60366BG60366BG-60366Chimeric degradation activating compound targeting EGFR
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on BG-60366.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG-60366.